© 2005 Oxford University Press
BRIEF COMMUNICATION |
Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families
Affiliations of authors: Clinical Genetics (NDK, MER, KEH, DG, EW, JL, TC, KO) and Breast Cancer Medicine Services (MER, LN), Department of Medicine; Gynecology (NDK, RRB) and Breast Services (PIB), Department of Surgery; Department of Epidemiology and Biostatistics (NM, SC); Department of Psychiatry and Behavioral Sciences (KEH); Memorial Sloan-Kettering Cancer Center, New York, NY
Correspondence to: Kenneth Offit, MD, MPH, Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Box 192, New York, NY 10021 (e-mail: offitk{at}mskcc.org).
Women from site-specific hereditary breast cancer families who carry a BRCA1 or BRCA2 mutation are at increased risk for ovarian cancer. It is less clear, however, whether individuals from hereditary breast cancer families who do not carry such a mutation are also at increased ovarian cancer risk. To determine whether women from BRCA mutation–negative hereditary breast cancer families are at increased risk for ovarian cancer, 199 probands from BRCA mutation–negative, site-specific breast cancer kindreds who consented to prospective follow-up at the time of genetic testing were identified. The incidence of new breast and ovarian cancers in probands and their families since receipt of their genetic test results was determined by questionnaire. The expected number of cancers and standardized incidence ratios (SIRs) were determined from age-specific cancer incidence rates from the Surveillance, Epidemiology, and End Results (SEER) program by using the method of Byar. All statistical tests were two-sided. During 2534 women-years of follow-up in 165 kindreds, 19 new cases of breast cancer were diagnosed, whereas only 6.07 were expected (SIR = 3.13, 95% confidence interval [CI] = 1.88 to 4.89; P<.001), and one case of ovarian cancer was diagnosed, whereas only 0.66 was expected (SIR = 1.52, 95% CI = 0.02 to 8.46; P = .48). These results suggest that women from BRCA mutation–negative, site-specific breast cancer families are not at increased risk for ovarian cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. D. Kauff and R. R. Barakat Risk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in BRCA1 or BRCA2 J. Clin. Oncol., July 10, 2007; 25(20): 2921 - 2927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Kauff and K. Offit Modeling Genetic Risk of Breast Cancer JAMA, June 20, 2007; 297(23): 2637 - 2639. [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Swisher and M.-C. King Defining Women at High Risk of Ovarian Cancer Cancer Res., March 15, 2007; 67(6): 2902 - 2902. [Full Text] [PDF]
|
|
|
|
|
|
G. C. Bagby and T. Pejovic Defining Women at High Risk of Ovarian Cancer Cancer Res., March 15, 2007; 67(6): 2902 - 2903. [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis, C. S. Rabkin, L. M. Brown, J. M. Allan, B. P. Alter, C. B. Ambrosone, C. B. Begg, N. Caporaso, S. Chanock, A. DeMichele, et al. Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations J Natl Cancer Inst, January 4, 2006; 98(1): 15 - 25. [Abstract] [Full Text] [PDF]
|
|